Drug intelligence / Profile preview

Synthamin-17 without electrolytes

Development stage
Unknown
Lead developer
Baxter Healthcare Corporation
Modality
Small Molecules
Administration
Intravenous, Parenteral
01

Overview

Synthamin-17 without electrolytes (Synthamin 17, 10.0% Amino Acid Intravenous Infusion without Electrolytes) is a sterile, hypertonic intravenous solution containing 15 essential and non-essential L-amino acids (including L-alanine, L-arginine, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine). Developed and manufactured by Baxter Healthcare, it is indicated for parenteral nutrition to provide a biologically available source of nitrogen for protein synthesis in patients who cannot absorb adequate oral nutrition. Additionally, the solution is being evaluated in clinical trials (such as those led by Austin Hospital) for its potential to improve kidney function and provide renal protection in critically ill, vasopressor-dependent adults.

Brand names
SYNTHAMIN 17SYNTHAMIN17SYNTHAMIN-17Synthamin 17 without electrolytesSynthamin17 without electrolytesSynthamin-17 without electrolytesSynthamin 17, 10.0% Amino Acid Intravenous Infusion without Electrolytes
Other names
10% amino acid intravenous infusion without electrolytesamino acids solution

Beyond the preview

Go deeper on Synthamin-17 without electrolytes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synthamin-17 without electrolytes.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call